Among TFE3-rearranged renal cell carcinomas, 11 of 23 tumors (48%), considering a 5% cutoff, and 9 of 23 tumors (39%), both with a 10% and a 20% threshold, were positive for CD13; a weak expression of the same marker was instead noticed for TFEB-rearranged renal cell carcinomas, with only 2 (22%) and 1 (11%) of 9 tumors staining positive, employing a 5% and both a 10% and 20% respectively considered. This evidence concerns the gene TFEB and renal cell carcinoma.